Viewing Study NCT02315703

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:30 PM
Ignite Modification Date: 2026-03-01 @ 4:13 PM
Study NCT ID: NCT02315703
Status: COMPLETED
Last Update Posted: 2025-02-04
First Post: 2014-12-09
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Sponsor: Janssen Vaccines & Prevention B.V.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Healthy View
None Acquired Immuno-Deficiency Syndrome View
None Acquired Immunodeficiency Syndrome Virus View
None adenovirus serotype 26 View
None Ad26.Mos.HIV View
None Modified Vaccinia Ankara View
None Glycoprotein View
None Adjuvant View
None Vaccine View
None Placebo View